Sonrgy Secures Exclusive License from UC San Diego to Commercialize Drug Delivery Nanotechnology

February 05, 2014 11:10 AM Eastern Standard Time
SAN DIEGO--(BUSINESS WIRE)--Sonrgy, Inc., a biotechnology company developing focused drug delivery technologies, has announced that it has entered into an exclusive license agreement with the University of California for the company's core technology, an ultrasound sensitive drug delivery platform.

"the SonRx technology addresses longstanding challenges related to stability and controlled release in nano-scale drug delivery"

The agreement grants the company the sole rights to develop and market the technology worldwide. Protecting the fundamental enabling technology establishes a significant barrier to potential competitors, and is a vital step towards bringing the platform to the clinic.

Based on research conducted in the lab of Prof. Sadik Esener at the UC San Diego Moores Cancer Center, "the SonRx technology addresses longstanding challenges related to stability and controlled release in nano-scale drug delivery," stated Dr. Michael Benchimol, Sonrgy's Chief Technology Officer. "We are excited to initiate the next steps of its commercial development."

About Sonrgy, Inc.

Sonrgy is a preclinical stage biotechnology company based in San Diego, California that is developing a targeted chemotherapy delivery platform to improve survival and quality of life for millions of cancer patients. Sonrgy's tiny nanocarriers safely transport potent chemotherapy drugs to cancer tumors and release high doses on command in response to a focused beam of ultrasound. These carriers deposit drugs directly at the tumor cell sites, avoiding the many serious side effects of toxic chemotherapy circulating in the blood stream. Nanocarriers can deliver chemotherapy before surgery to reduce tumor size, after surgery to prevent recurrence and in situations when surgery is not possible to arrest tumor growth. This distinctive approach to delivering chemotherapy can be applied to many cancer tumors and enables more intensive treatment of the cancer, potentially improving effectiveness while reducing harmful effects on the rest of the body.

Contacts
Sonrgy, Inc.
Michael Benchimol
858-939-9983
[email protected]

Suggested Articles

Purdue's reformulated OxyContin may stop patients from snorting or injecting the drug, but it doesn't curb abuse overall, an FDA panel determined.

Roche is gearing up to launch an eye implant to make its Lucentis AMD drug easier to use. But the drugmaker has even bigger plans for the device.

Delivery specialist IntelGenx struck two deals to develop oral films for prescription psychedelics this summer with Canada's Cybin and ATAI.